Aesthetic medicine continues to enjoy exponential growth, and both patients and clinicians look forward to benefiting from the latest dermal fillers and neurotoxin trends. As the medical aesthetics industry evolves, new and better injectables (as both dermal fillers and neurotoxins are often called) are preparing to make their market debut or have already been released. Here are five of the newest leading injectables you can expect to start seeing everywhere, now or in the near future.
DaxibotulinumtoxinA, or DAXI, is a new botulinum A toxin for glabellar wrinkles. What sets this product apart from the others is its longevity. Neurotoxins typically maintain their intended effect for only three to four months while DAXI lasts up to seven. In addition, DAXI is the first botulinum type A toxin that doesn’t require human or animal-derived additives nor human serum albumin, a foreign stabilizing agent. This makes DAXI a “cleaner” injectable option. This game-changing product is not yet available in the U.S. or any other country but will be released in Winter 2021 after receiving FDA approval.
Qwo is the first and only FDA-approved injectable for treating moderate to severe cellulite. The shot works by using collagen-degrading enzymes to break down the fibrous bands tethering skin to muscle. This releases the mesh-like tension-patterning through which fat tends to bulge, resulting in a new smooth appearance without lumps, bumps, or irregularities. Endo Aesthetics has also announced that their product increases collagen synthesis. This enables the skin to thicken over time to provide an additional layer of camouflage for the fat deposits beneath it. Improvements in the appearance of cellulite can last up to four years following a series of treatments. Qwo won its FDA approval in July 2021 and is now available nationwide.
Juvéderm Volite is an injectable treatment intended to improve skin quality for up to nine months. The skin-conditioning hyaluronic acid (HA) gel helps reduce the appearance of fine lines and corrects the overall tone and texture of the skin itself. The main desire is to achieve a more hydrated look and increase the skin’s elasticity with the HA’s high water-binding capacity. Only available in Europe and Canada, this product is expected to surface in the U.S. later in the year.
Cytrellis microcoring, also known as fractional tissue extraction, is a facelift without scars! The device painlessly removes up to eight percent of treated skin by drilling out tiny columns and allowing them to cinch close for a tighter, smoother surface. This process does not affect the muscles of the face like a surgical facelift and recovery is fairly minimal. You can treat the full face, neck, and select areas of sagging on the body. This device received its FDA approval earlier this year.
This hyaluronic acid is a volumizer for cheeks whose highly flexible consistency enables it to “flow” seamlessly with the natural movements of the face. (This ensures patients can avoid the “chunky” look that can occur with less mobile injectables.) In addition, this supportive dermal filler replaces a substance in the skin that is lost through the aging process.) And because Restylane Volyme can be layered in the more superficial subcutaneous tissue, it’s ideal for older patients and those with thinner skin. With staying power that lasts as long as 18 months, it’s one of the longest-lasting products on the market.
Next-generation medical aesthetics injectables are here today, or coming your way soon! By adding these newest leading products to your patient arsenal, and to stay on top of trends in ways that increase customer loyalty, build your clinic’s reputation, and increase your business’s ROI, read more on the AAAMS Aesthetic Network.